Clinical trial NCT00361166: Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
Official title: A Randomized, Double Blind, Multi-Center Study to Assess the Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol or Risperidone to Schizophrenic Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Schizophrenia
Keywords: Schizophrenia
psychosis
delusions
hallucination
Lead sponsor: ACADIA Pharmaceuticals Inc.
Sponsor class: INDUSTRY
First posted: 2006-08-07
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to determine whether a combination of ACP-103 (the study medication) with either haloperidol or risperidone will show antipsychotic efficacy and that it is safe and well tolerated. Further purposes of this study are to determine whether ACP-103, in combination with either haloperidol or risperidone, will enhance their antipsychotic effectiveness, demonstrate effectiveness against the negative symptoms, improve motoric tolerability, and is safe and well tolerated.

This is a seven-week study (one week screening and six weeks of study medication) where a total of 400 patients who meet entrance criteria will randomly be assigned to receive one of five groups of study treatments of either low dose haloperidol plus ACP-103, low dose haloperidol plus placebo (a substance similar to a sugar pill), low dose risperidone plus ACP-103, low dose risperidone plus placebo, or high dose risperidone plus placebo. The study will begin with with a three to seven day drug-free period followed by six weeks of a stable daily dosage of study medication. Study subjects will be treated as hospital in-patients during screening and for the first 14 days of the study. Study subjects will be closely monitored throughout the study.


Eligibility criteria: Inclusion Criteria:

* male or female subjects ages 18-65 diagnosed with schizophrenia
* experiencing an acute exacerbation of psychosis
* has had prior response to antipsychotic therapy within the previous 3 years
* female subjects must be of non-childbearing potential or must comply with double-barrier protection methods against conception
* ability of subject or caregiver or legally authorized representative to provide informed consent
* subjects must be hospitalized at screening and must be willing to remain in the hospital at least 14 days after baseline and must comply with all study events through completion of the study

Exclusion Criteria:

* inability of the subject or caregiver or legally authorized representative to provide consent
* any female subject who is pregnant or breast feeding
* any subject with concurrent mental illness or disability
* any subject considered to be a danger to themselves or others
* recent use of certain antipsychotics or other medications that might interfere with this study's medication
* abnormal clinical laboratory values
* presence, or recent history, of serious medical conditions or drug abuse
* likely allergy or sensitivity to ACP-103, haloperidol, or risperidone, based on known allergies to drugs of the same class
* any subject who has participated in a prior clinical trial of ACP-103
* any subject judged by the Principal Investigator to be inappropriate for the study

Primary outcomes:
measure: Total score on the Positive and Negative Symptom Scale (PANSS).
Secondary outcomes:
measure: Clinical Global Impression-Severity (CGI-S), Simpson Angus Scale (SAS), Barnes Akathisia Scale (BAS), Calgary Depression Scale for Schizophrenia (CDSS)
Other outcomes:
Locations:
city: Cerritos
country: United States
state: California
city: Garden Grove
country: United States
state: California
city: Glendale
country: United States
state: California
city: Paramount
country: United States
state: California
city: Pico Rivera
country: United States
state: California
city: San Diego
country: United States
state: California
city: San Diego
country: United States
state: California
city: Washington
country: United States
state: District of Columbia
city: St. Louis
country: United States
state: Missouri
city: Austin
country: United States
state: Texas
city: Irving
country: United States
state: Texas
city: Salvador
country: Brazil
state: BA
city: Aparecida de Goiânia
country: Brazil
state: GO
city: Curitiba
country: Brazil
state: PR
city: Curitiba
country: Brazil
state: PR
city: Rio de Janeiro
country: Brazil
state: RJ
city: São Paulo
country: Brazil
state: SP
Study officials:
affiliation: ACADIA Pharmaceuticals Inc.
name: Daniel van Kammen, MD, PhD
role: STUDY_CHAIR
References: